Amgen (AMGN) Declines More Than Market: Some Information for Investors

Amgen (AMGN) shares recently closed down 1.17%, underperforming the S&P 500, though they have outpaced the broader Medical sector over the past month. Investors are focused on the upcoming August 5, 2025 earnings report, where Zacks consensus estimates project Q3 EPS of $5.22 (+5.03% YoY) and revenue of $8.86 billion (+5.64% YoY). Despite a slight upward revision in recent analyst EPS estimates, the stock maintains a Zacks Rank of #3 (Hold). Valuation presents a mixed picture, with AMGN trading at a forward P/E of 14.31, a discount to its industry's 18.7 average, but its PEG ratio of 2.7 exceeds the industry average of 1.48.

Analysis

Amgen (AMGN) exhibited short-term underperformance, with its shares declining 1.17% against the S&P 500's 0.01% loss in the last session. However, its one-month gain of 2.98% has outpaced the broader Medical sector's 1.59% loss. The market's attention is now fixed on the upcoming earnings release, with consensus estimates projecting solid year-over-year growth for the quarter, including a 5.64% increase in revenue to $8.86 billion and a 5.03% rise in EPS to $5.22. This positive fundamental outlook is further supported by a slight upward revision in the Zacks Consensus EPS estimate over the past month. Despite these constructive indicators, the stock holds a neutral Zacks Rank of #3 (Hold). The valuation presents a mixed picture: AMGN trades at a forward P/E of 14.31, a notable discount to its industry's average of 18.7. Conversely, its PEG ratio of 2.7 is significantly higher than the industry average of 1.48, suggesting the stock's price may be elevated relative to its expected earnings growth rate.

Key Decisions for Investors

• Investors should weigh the attractive valuation based on its forward P/E discount against the cautionary signal from its high PEG ratio, which suggests the price may not be justified by the expected growth.
• The upcoming August 5th earnings report is a critical catalyst; meeting or exceeding the consensus growth estimates of over 5% for both revenue and EPS is crucial to support the stock's current trajectory.
• Given the neutral 'Hold' rating and conflicting valuation metrics, a prudent approach could be to await the earnings results for confirmation of the growth narrative before initiating or adding to a position.